Merck-Seagen to be the Biggest Pharma Acquisition Since 2020

Merck’s proposed acquisition of Seagen will not come into fruition until after the firms’ respective quarterly report is announced on July 28.

Upcoming digital information for the bladder cancer therapy Padcev makes the actual value of Seagen more convoluted; furthermore, the current patent dispute between Daiichi Sankyo and Seagen makes proceedings difficult.

The outcome of the Padlev trial is of particular importance since Seagen is hoping to market the medicine as a primary treatment, even though it is presently only licenced for secondary bladder cancer; this change would increase its potential sales by billions.

Regarding the Daiichi Sankyo patent verdict, the court determined that Seagen’s patents were violated and ruled Seagen to be compensated $41.8 million.

There is talk of the merger costing over $40 billion, therefore becoming the largest financial pharmaceutical transaction since 2020.